{"id":9373,"date":"2026-10-31T03:16:50","date_gmt":"2026-10-31T00:16:50","guid":{"rendered":"https:\/\/merkezlaboratuvari.com\/?p=9373"},"modified":"2026-10-31T03:16:50","modified_gmt":"2026-10-31T00:16:50","slug":"anti-hbs-nedir","status":"publish","type":"post","link":"https:\/\/merkezlaboratuvari.com\/ar\/anti-hbs-nedir\/","title":{"rendered":"Anti-HBs Nedir? Pozitif ve Negatif Sonu\u00e7 Ne Demek"},"content":{"rendered":"<p>Anti-HBs nedir sorusunun k\u0131sa yan\u0131t\u0131: anti-HBs, hepatit B vir\u00fcs\u00fcn\u00fcn y\u00fczey antijenine (HBsAg) kar\u015f\u0131 v\u00fccudun \u00fcretti\u011fi antikordur ve hepatit B&#8217;ye kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n g\u00f6stergesi olarak kullan\u0131l\u0131r. Pozitif sonu\u00e7 genellikle hepatit B a\u015f\u0131s\u0131na ya da iyile\u015fmi\u015f bir enfeksiyona ba\u011fl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131, negatif sonu\u00e7 ise o anda koruyucu d\u00fczeyde antikor saptanmad\u0131\u011f\u0131n\u0131 g\u00f6sterir.<\/p>\n<p>Bu sayfada anti-HBs&#8217;nin nas\u0131l olu\u015ftu\u011fu, pozitif, negatif ve y\u00fcksek sonucun genel anlam\u0131, de\u011ferin birim ve y\u00f6ntemle ili\u015fkisi, zaman i\u00e7indeki de\u011fi\u015fimi ve a\u015f\u0131 sonras\u0131 de\u011ferlendirmenin k\u0131lavuzlardaki \u00e7er\u00e7evesi anlat\u0131l\u0131r. Bilgiler genel bilgilendirme ama\u00e7l\u0131d\u0131r; ki\u015fisel de\u011ferlendirme i\u00e7in hekime ba\u015fvurulmal\u0131d\u0131r.<\/p>\n<blockquote>\n<p><strong>\u00d6zet<\/strong><br \/>\n&#8211; Anti-HBs, hepatit B y\u00fczey antijenine kar\u015f\u0131 olu\u015fan antikordur; a\u015f\u0131dan ya da iyile\u015fmi\u015f enfeksiyondan sonra geli\u015fir.<br \/>\n&#8211; A\u015f\u0131 sonras\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6stergesi olarak k\u0131lavuzlarda kullan\u0131lan genel de\u011fer 10 mIU\/mL ve \u00fczeridir; laboratuvar raporundaki aral\u0131k esast\u0131r.<br \/>\n&#8211; Pozitifli\u011fin a\u015f\u0131dan m\u0131 enfeksiyondan m\u0131 geldi\u011fi anti-HBc ile ay\u0131rt edilir.<br \/>\n&#8211; Anti-HBs zamanla azalabilir; bu, her durumda koruman\u0131n bitti\u011fi anlam\u0131na gelmez.<br \/>\n&#8211; Sonu\u00e7 tek ba\u015f\u0131na tan\u0131 koydurmaz; HBsAg ve anti-HBc ile birlikte hekim taraf\u0131ndan yorumlan\u0131r.<\/p>\n<\/blockquote>\n<h2>Anti-HBs Nedir ve Nas\u0131l Olu\u015fur?<\/h2>\n<p>Hepatit B vir\u00fcs\u00fcn\u00fcn (HBV) d\u0131\u015f zarf\u0131nda HBsAg ad\u0131 verilen bir protein bulunur. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi bu proteine kar\u015f\u0131 anti-HBs antikorunu \u00fcretebilir. Antikor iki yoldan olu\u015fur: hepatit B a\u015f\u0131s\u0131ndan sonra ya da enfeksiyon iyile\u015ftikten sonra. CDC&#8217;ye g\u00f6re ge\u00e7irilmi\u015f enfeksiyonda HBsAg azald\u0131ktan sonra anti-HBs&#8217;nin ortaya \u00e7\u0131kmas\u0131 iyile\u015fmenin g\u00f6stergesidir (CDC 2023).<\/p>\n<p>Anti-HBs, hepatit B serolojisinin \u00fc\u00e7 temel testinden biridir; di\u011ferleri <a href=\"\/hbsag-nedir\/\">HBsAg<\/a> ve <a href=\"\/test-listesi\/anti-hbc-total\/\">total anti-HBc<\/a> testleridir. \u00dc\u00e7\u00fcn\u00fcn birlikte nas\u0131l okundu\u011fu hepatit B tahlilleri yaz\u0131s\u0131nda ele al\u0131nmaktad\u0131r. Bkz. <a href=\"\/hepatit-b-tahlilleri\/\">Hepatit B Tahlilleri<\/a>.<\/p>\n<h2>Anti-HBs Pozitif Ne Demek?<\/h2>\n<p>Anti-HBs pozitifli\u011fi genel olarak hepatit B&#8217;ye kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k geli\u015fti\u011fini g\u00f6sterir. Bu ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n kayna\u011f\u0131 iki farkl\u0131 olabilir ve bunu ay\u0131rt eden test anti-HBc&#8217;dir:<\/p>\n<ul>\n<li><strong>Anti-HBs pozitif, anti-HBc negatif:<\/strong> A\u015f\u0131ya ba\u011fl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k d\u00fc\u015f\u00fcn\u00fcl\u00fcr. Anti-HBc a\u015f\u0131yla olu\u015fmaz (CDC 2023).<\/li>\n<li><strong>Anti-HBs pozitif, anti-HBc pozitif (HBsAg negatif):<\/strong> Ge\u00e7irilmi\u015f ve iyile\u015fmi\u015f enfeksiyon sonras\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k d\u00fc\u015f\u00fcn\u00fcl\u00fcr.<\/li>\n<\/ul>\n<p>HBsAg&#8217;nin de pozitif oldu\u011fu bir tablo farkl\u0131 bir de\u011ferlendirme gerektirir ve hekim taraf\u0131ndan ele al\u0131n\u0131r. Anti-HBs pozitifli\u011fi tek ba\u015f\u0131na &#8220;hepatit B yok&#8221; ya da &#8220;her durumda tam koruma&#8221; h\u00fckm\u00fc vermez; sonu\u00e7 di\u011fer testlerle birlikte yorumlan\u0131r.<\/p>\n<h2>Anti-HBs Ka\u00e7 Olmal\u0131? Sonu\u00e7 Nas\u0131l Okunur?<\/h2>\n<p>A\u015f\u0131 serisini tamamlayan ki\u015filerde ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6stergesi olarak kullan\u0131lan genel k\u0131lavuz de\u011feri, serinin bitiminden 1\u20132 ay sonra anti-HBs&#8217;nin 10 mIU\/mL ve \u00fczerinde olmas\u0131d\u0131r (CDC ACIP 2018). TKAD 2023 k\u0131lavuzu da bula\u015f riski olanlarda a\u015f\u0131 sonras\u0131 etkin antikor d\u00fczeyinin olu\u015fup olu\u015fmad\u0131\u011f\u0131n\u0131n kontrol edilmesini belirtir. Bu de\u011fer bir &#8220;normal aral\u0131k&#8221; de\u011fil, ba\u011f\u0131\u015f\u0131kl\u0131k i\u00e7in kullan\u0131lan bir e\u015fiktir; kesin aral\u0131k ve birim laboratuvar\u0131n y\u00f6ntemine g\u00f6re raporda yazar.<\/p>\n\n<figure class=\"wp-block-table\"><table>\n<thead>\n<tr>\n<th>Sonu\u00e7<\/th>\n<th>Genel yorum \u00e7er\u00e7evesi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Referans\/pozitiflik e\u015fi\u011finin alt\u0131 (k\u0131lavuz de\u011feri: 10 mIU\/mL alt\u0131)<\/td>\n<td>Koruyucu d\u00fczeyde antikor saptanmam\u0131\u015ft\u0131r<\/td>\n<\/tr>\n<tr>\n<td>E\u015fik ve \u00fczeri (k\u0131lavuz de\u011feri: 10 mIU\/mL ve \u00fczeri)<\/td>\n<td>Ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6stergesi olarak de\u011ferlendirilir<\/td>\n<\/tr>\n<tr>\n<td>Laboratuvar\u0131n kendi e\u015fi\u011fi ve birimi<\/td>\n<td>Sonu\u00e7 raporunda belirtilir; yorumda rapordaki de\u011fer esas al\u0131n\u0131r<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/figure>\n\n<h3>Birim ve y\u00f6ntem farklar\u0131<\/h3>\n<ul>\n<li><strong>Birim:<\/strong> Raporlarda mIU\/mL ya da IU\/L g\u00f6r\u00fclebilir; bu iki birim ayn\u0131 de\u011feri ifade eder (uluslararas\u0131 birim tan\u0131m\u0131 gere\u011fi 1 mIU\/mL = 1 IU\/L). K\u0131lavuzlarda da yaz\u0131m fark\u0131 olabilir; \u00f6rne\u011fin TKAD metninde birim &#8220;IU\/ml&#8221; olarak yaz\u0131lm\u0131\u015ft\u0131r.<\/li>\n<li><strong>Y\u00f6ntem:<\/strong> Farkl\u0131 analiz y\u00f6ntemleri farkl\u0131 \u00f6l\u00e7\u00fcm aral\u0131klar\u0131 ve e\u015fikler kullanabilir; bu nedenle farkl\u0131 laboratuvarlar\u0131n say\u0131lar\u0131 do\u011frudan k\u0131yaslanmaz.<\/li>\n<li><strong>Rapor \u00fcst s\u0131n\u0131r\u0131:<\/strong> Baz\u0131 y\u00f6ntemlerde belirli bir de\u011ferin \u00fczerindeki sonu\u00e7lar tam say\u0131 yerine &#8220;b\u00fcy\u00fckt\u00fcr&#8221; i\u015faretiyle raporlan\u0131r. Kullan\u0131lan y\u00f6ntemin \u00f6l\u00e7\u00fcm aral\u0131\u011f\u0131 ve \u00fcst raporlama s\u0131n\u0131r\u0131 sonu\u00e7 raporunda belirtilir.<\/li>\n<\/ul>\n<h2>Anti-HBs Negatif Ne Demek?<\/h2>\n<p>Anti-HBs d\u00fc\u015f\u00fckl\u00fc\u011f\u00fc, yani sonucun e\u015fi\u011fin alt\u0131nda kalmas\u0131 ya da negatif \u00e7\u0131kmas\u0131, o anda koruyucu d\u00fczeyde antikor saptanmad\u0131\u011f\u0131n\u0131 g\u00f6sterir. Nedeni tek ba\u015f\u0131na testten anla\u015f\u0131lmaz; \u015funlar olabilir:<\/p>\n<ul>\n<li>Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ya da vir\u00fcsle hi\u00e7 kar\u015f\u0131la\u015fmam\u0131\u015f olmak,<\/li>\n<li>A\u015f\u0131 serisini tamamlam\u0131\u015f olsa bile yeterli yan\u0131t\u0131n olu\u015fmam\u0131\u015f olmas\u0131,<\/li>\n<li>Daha \u00f6nce olu\u015fmu\u015f antikorun zamanla azalm\u0131\u015f olmas\u0131,<\/li>\n<li>Kronik hepatit B enfeksiyonu (bu durumda HBsAg pozitiftir ve anti-HBs genellikle negatiftir; CDC 2023).<\/li>\n<\/ul>\n<p>TKAD 2023&#8217;e g\u00f6re 40 ya\u015f \u00fcst\u00fc olmak, TKAD 2023 ve CDC ACIP 2018&#8217;e g\u00f6re erkek cinsiyet, ileri ya\u015f, obezite, sigara kullan\u0131m\u0131, kronik hastal\u0131klar ve ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 bask\u0131layan durumlar a\u015f\u0131ya verilen yan\u0131t\u0131 azaltabilen etkenler aras\u0131ndad\u0131r. Anti-HBs negatifli\u011fi sonras\u0131nda yap\u0131lacak i\u015flemlere hekim karar verir.<\/p>\n<h2>Anti-HBs Y\u00fcksekli\u011fi Ne Anlama Gelir?<\/h2>\n<p>Anti-HBs y\u00fcksekli\u011fi tek ba\u015f\u0131na bir hastal\u0131k belirtisi de\u011fildir. A\u015f\u0131ya ya da ge\u00e7irilmi\u015f enfeksiyona verilen g\u00fc\u00e7l\u00fc bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131 yans\u0131t\u0131r. &#8220;Anti-HBs 1000&#8221; gibi \u00e7ok y\u00fcksek rapor de\u011ferleri s\u0131k\u00e7a merak edilir; bu say\u0131 y\u00f6nteme ve birime ba\u011fl\u0131 olarak raporlan\u0131r. CDC kaynaklar\u0131nda ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6stergesi olarak 10 mIU\/mL e\u015fi\u011fi kullan\u0131l\u0131r ve bunun \u00fczerindeki de\u011ferler i\u00e7in ayr\u0131 bir e\u015fik tan\u0131mlanmaz; TKAD k\u0131lavuzu ise ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 bask\u0131layan tedavi alan ya da nakil sonras\u0131 baz\u0131 \u00f6zel gruplarda farkl\u0131 hedef d\u00fczeylerden s\u00f6z eder. Bu gruplarda yorum hekime aittir. Y\u00fcksek sonu\u00e7 \u00e7\u0131kt\u0131\u011f\u0131nda, HBsAg ve anti-HBc ile birlikte de\u011ferlendirme yap\u0131lmas\u0131 i\u00e7in hekime ba\u015fvurulabilir.<\/p>\n<h2>Anti-HBs Zamanla D\u00fc\u015fer mi?<\/h2>\n<p>Evet, anti-HBs d\u00fczeyi zaman i\u00e7inde azalabilir. CDC&#8217;nin ACIP raporuna g\u00f6re a\u015f\u0131 serisine ba\u015flang\u0131\u00e7ta yan\u0131t vermi\u015f ve ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 normal olan ki\u015filerde d\u00fczey sonradan 10 mIU\/mL&#8217;nin alt\u0131na inse bile koruma s\u00fcrer; bu ki\u015filerde rutin hat\u0131rlatma dozu ve d\u00fczenli test \u00f6nerilmedi\u011fi belirtilir. TKAD 2023 k\u0131lavuzu da a\u015f\u0131 sonras\u0131 koruyucu d\u00fczey saptananlarda ilave hat\u0131rlatma dozuna gerek olmad\u0131\u011f\u0131n\u0131 belirtir. Ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 bask\u0131lanm\u0131\u015f ki\u015filer ve belirli sa\u011fl\u0131k gruplar\u0131nda de\u011ferlendirme farkl\u0131d\u0131r; bu karar hekime aittir.<\/p>\n<h2>A\u015f\u0131 Sonras\u0131 Anti-HBs Ne Zaman ve Kimlerde Bak\u0131l\u0131r?<\/h2>\n<p>CDC&#8217;nin ACIP raporu, rutin hepatit B a\u015f\u0131lamas\u0131ndan sonra herkes i\u00e7in test \u00f6nermez. A\u015f\u0131 sonras\u0131 anti-HBs testi \u015fu gruplar i\u00e7in belirtilmi\u015ftir: kan ve v\u00fccut s\u0131v\u0131lar\u0131yla temas riski ta\u015f\u0131yan sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131, hemodiyaliz hastalar\u0131, HIV ile ya\u015fayanlar ve ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 bask\u0131lanm\u0131\u015f ki\u015filer, HBsAg pozitif ki\u015finin cinsel partnerleri ve HBsAg pozitif anneden do\u011fan bebekler. Test, serinin son dozundan 1\u20132 ay sonra; bebeklerde ise 9\u201312. ay aras\u0131nda yap\u0131l\u0131r. Erken \u00f6l\u00e7\u00fcmde, bebe\u011fe verilen ba\u011f\u0131\u015f\u0131kl\u0131k globulinden gelen pasif antikor sonucu yan\u0131ltabilir.<\/p>\n<p>Ayn\u0131 rapora g\u00f6re e\u015fi\u011fin alt\u0131nda kalan ki\u015filer i\u00e7in ikinci bir seri ve yeniden test tarif edilir; yine yan\u0131t olu\u015fmazsa HBsAg bak\u0131lmas\u0131 \u00f6nerilir. Bunlar k\u0131lavuz i\u00e7erikleridir; ki\u015fiye \u00f6zg\u00fc a\u015f\u0131 ve test plan\u0131 hekim taraf\u0131ndan yap\u0131l\u0131r. Hepatit B ba\u011f\u0131\u015f\u0131kl\u0131k globulini (HBIG) uygulanan ki\u015filerde pasif antikor 4\u20136 ay \u00f6l\u00e7\u00fclebilir, bu nedenle bu d\u00f6nemde bak\u0131lan anti-HBs ki\u015finin kendi ba\u011f\u0131\u015f\u0131kl\u0131k durumunu yans\u0131tmayabilir (CDC 2023).<\/p>\n<h2>Numune ve Sonu\u00e7 S\u00fcresi<\/h2>\n<p>Anti-HBs testinin numune t\u00fcr\u00fc, a\u00e7l\u0131k gereksinimi ve raporlama zaman\u0131 <a href=\"\/test-listesi\/anti-hbs\/\">Anti-HBs test sayfas\u0131nda<\/a> belirtilir; genel bilgi i\u00e7in <a href=\"\/kan-tahlili-sonucu-ne-zaman-cikar\/\">kan tahlili sonucu ne zaman \u00e7\u0131kar<\/a> sayfas\u0131na bak\u0131labilir. A\u015f\u0131 ve ba\u011f\u0131\u015f\u0131kl\u0131k globulini \u00f6yk\u00fcs\u00fc hekimle ve laboratuvarla payla\u015f\u0131lmal\u0131d\u0131r.<\/p>\n<h2>Ne Zaman Hekime Ba\u015fvurulmal\u0131?<\/h2>\n<p>Anti-HBs nedir sorusunun bu yaz\u0131daki yan\u0131t\u0131 genel bilgidir; sonu\u00e7 tek ba\u015f\u0131na yorumlan\u0131p a\u015f\u0131 ya da ba\u015fka bir karar i\u00e7in dayanak yap\u0131lmamal\u0131d\u0131r. Sonu\u00e7 negatifse ya da e\u015fi\u011fin alt\u0131ndaysa, HBsAg veya anti-HBc ile uyumsuz g\u00f6r\u00fcn\u00fcyorsa, ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 bask\u0131layan bir hastal\u0131k ya da tedavi s\u00f6z konusuysa, gebelik varsa veya sa\u011fl\u0131k \u00e7al\u0131\u015fan\u0131 gibi temas riski ta\u015f\u0131yan bir meslek grubundaysa de\u011ferlendirme hekim taraf\u0131ndan yap\u0131lmal\u0131d\u0131r.<\/p>\n<h2>S\u0131k\u00e7a Sorulan Sorular<\/h2>\n<h3>Anti-HBs nedir?<\/h3>\n<p>Anti-HBs, hepatit B vir\u00fcs\u00fcn\u00fcn y\u00fczey antijenine (HBsAg) kar\u015f\u0131 olu\u015fan antikordur. Hepatit B a\u015f\u0131s\u0131ndan sonra ya da enfeksiyon iyile\u015ftikten sonra olu\u015fur ve ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n g\u00f6stergesi olarak kullan\u0131l\u0131r. Sonu\u00e7, HBsAg ve anti-HBc ile birlikte hekim taraf\u0131ndan yorumlan\u0131r.<\/p>\n<h3>Anti-HBs pozitif ne demek?<\/h3>\n<p>Anti-HBs pozitifli\u011fi genel olarak hepatit B&#8217;ye kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k geli\u015fti\u011fini g\u00f6sterir. Bu ba\u011f\u0131\u015f\u0131kl\u0131k a\u015f\u0131dan ya da ge\u00e7irilmi\u015f enfeksiyondan gelebilir; ayr\u0131m i\u00e7in anti-HBc sonucuna bak\u0131l\u0131r. Yorum hekime aittir.<\/p>\n<h3>Anti-HBs negatif ne demek?<\/h3>\n<p>Anti-HBs&#8217;nin negatif ya da referans de\u011ferin alt\u0131nda olmas\u0131, o anda koruyucu d\u00fczeyde antikor saptanmad\u0131\u011f\u0131 anlam\u0131na gelir. Bunun nedeni hi\u00e7 a\u015f\u0131lanmamak ya da kar\u015f\u0131la\u015f\u0131lmamak, a\u015f\u0131ya yeterli yan\u0131t olu\u015fmamas\u0131 veya antikorun zamanla azalmas\u0131 olabilir. Nedenin belirlenmesi HBsAg ve anti-HBc ile birlikte hekim taraf\u0131ndan yap\u0131l\u0131r.<\/p>\n<h3>Anti-HBs ka\u00e7 olmal\u0131?<\/h3>\n<p>A\u015f\u0131 serisini tamamlayan ki\u015filerde ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6stergesi olarak kullan\u0131lan genel k\u0131lavuz de\u011feri 10 mIU\/mL ve \u00fczeridir (CDC). Birim, y\u00f6ntem ve e\u015fik laboratuvara g\u00f6re de\u011fi\u015febilir; laboratuvar raporundaki aral\u0131k esast\u0131r.<\/p>\n<h3>Anti-HBs y\u00fcksek \u00e7\u0131karsa ne demek?<\/h3>\n<p>Y\u00fcksek anti-HBs tek ba\u015f\u0131na bir hastal\u0131k belirtisi de\u011fildir; a\u015f\u0131ya ya da ge\u00e7irilmi\u015f enfeksiyona verilen g\u00fc\u00e7l\u00fc bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131 yans\u0131t\u0131r. Rapordaki say\u0131sal de\u011ferin b\u00fcy\u00fckl\u00fc\u011f\u00fc y\u00f6ntemle de ili\u015fkilidir. Sonu\u00e7 di\u011fer hepatit B testleriyle birlikte hekim taraf\u0131ndan yorumlan\u0131r.<\/p>\n<h3>Anti-HBs zamanla d\u00fc\u015fer mi?<\/h3>\n<p>Evet, anti-HBs d\u00fczeyi zaman i\u00e7inde azalabilir. CDC&#8217;nin ACIP raporuna g\u00f6re a\u015f\u0131ya yan\u0131t vermi\u015f ve ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 normal ki\u015filerde d\u00fczey sonradan 10 mIU\/mL&#8217;nin alt\u0131na inse bile koruma s\u00fcrer. Bu de\u011ferlendirme hekime aittir.<\/p>\n<h3>Hepatit B a\u015f\u0131s\u0131ndan sonra anti-HBs ne zaman bak\u0131l\u0131r?<\/h3>\n<p>CDC&#8217;nin ACIP raporuna g\u00f6re, a\u015f\u0131 sonras\u0131 test gerekti\u011finde serinin son dozundan 1\u20132 ay sonra yap\u0131l\u0131r; rutin a\u015f\u0131lamada herkes i\u00e7in test \u00f6nerilmez. Hangi ki\u015filerde ve ne zaman bak\u0131laca\u011f\u0131na hekim karar verir.<\/p>\n<h2>\u0130lgili Testler ve Yaz\u0131lar<\/h2>\n<ul>\n<li><a href=\"\/test-listesi\/anti-hbs\/\">Anti-HBs test sayfas\u0131<\/a><\/li>\n<li><a href=\"\/hbsag-nedir\/\">HBsAg nedir? Pozitif ve negatif ne anlama gelir<\/a><\/li>\n<li><a href=\"\/test-listesi\/anti-hbc-total\/\">Anti-HBc total test sayfas\u0131<\/a><\/li>\n<li><a href=\"\/kan-tahlili-sonucu-ne-zaman-cikar\/\">Kan tahlili sonucu ne zaman \u00e7\u0131kar<\/a><\/li>\n<li><a href=\"\/hepatit-b-tahlilleri\/\">Hepatit B Tahlilleri<\/a><\/li>\n<li><a href=\"\/anti-hbc-nedir\/\">Anti-HBc Nedir?<\/a><\/li>\n<\/ul>\n<blockquote>\n<p><strong>Merkez T\u0131bbi Tahlil Laboratuvar\u0131<\/strong><br \/>\nKayaba\u015f\u0131, Kaya\u015fehir Blv. Sitesi No:40, 34220 Ba\u015fak\u015fehir\/\u0130stanbul<br \/>\nTelefon: 0212 610 01 30 (WhatsApp hatt\u0131 mevcuttur)<br \/>\n\u00c7al\u0131\u015fma saatleri: Pazartesi\u2013Cumartesi 08:30\u201318:00, Pazar kapal\u0131<br \/>\nRandevu uygulamas\u0131 bulunmamaktad\u0131r; hasta kabul\u00fc \u00e7al\u0131\u015fma saatleri i\u00e7inde yap\u0131lmaktad\u0131r.<br \/>\nArap\u00e7a bilgilendirme hizmeti mevcuttur. Sonu\u00e7lar online olarak sorgulanabilmektedir.<br \/>\n\u0130leti\u015fim: <a href=\"\/iletisim\/\">ileti\u015fim sayfas\u0131<\/a><\/p>\n<p><strong>Uyar\u0131:<\/strong> Bu sayfa yaln\u0131zca genel bilgilendirme ama\u00e7l\u0131d\u0131r; tan\u0131, tedavi veya t\u0131bbi karar yerine ge\u00e7mez. Test sonu\u00e7lar\u0131 hekim taraf\u0131ndan de\u011ferlendirilmelidir.<\/p>\n<\/blockquote>\n<p><strong>Kaynaklar<\/strong>:<br \/>\n&#8211; <a href=\"https:\/\/www.cdc.gov\/mmwr\/volumes\/67\/rr\/rr6701a1.htm\" rel=\"nofollow noopener\" target=\"_blank\">Schillie S ve ark., Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the ACIP, MMWR Recomm Rep 2018;67(1)<\/a><br \/>\n&#8211; <a href=\"https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/rr\/rr7201a1.htm\" rel=\"nofollow noopener\" target=\"_blank\">Conners EE ve ark., Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations, United States, 2023, MMWR Recomm Rep 2023;72(RR-1)<\/a><br \/>\n&#8211; <a href=\"https:\/\/www.tkad.org.tr\/wp-content\/uploads\/2023\/11\/TURKIYE-HEPATIT-B-TANI-VE-TEDAVI-KLAVUZU-2023.pdf\" rel=\"nofollow noopener\" target=\"_blank\">T\u00fcrk Karaci\u011fer Ara\u015ft\u0131rmalar\u0131 Derne\u011fi (TKAD), T\u00fcrkiye Hepatit B Tan\u0131 ve Tedavi K\u0131lavuzu, 2023<\/a><\/p>\n<p><strong>Son g\u00fcncelleme<\/strong>: 30 Ekim 2026<\/p>\n\n<script type=\"application\/ld+json\">\n{\n \"@context\": \"https:\/\/schema.org\",\n \"@graph\": [\n {\n \"@type\": \"MedicalWebPage\",\n \"name\": \"Anti-HBs Nedir? Pozitif ve Negatif Sonu\u00e7 Ne Demek\",\n \"url\": \"https:\/\/merkezlaboratuvari.com\/anti-hbs-nedir\/\",\n \"inLanguage\": \"tr\",\n \"about\": { \"@type\": \"MedicalTest\", \"name\": \"Anti-HBs (hepatit B y\u00fczey antikoru)\" },\n \"dateModified\": \"2026-10-30\",\n \"publisher\": { \"@type\": \"Organization\", \"name\": \"Merkez T\u0131bbi Tahlil Laboratuvar\u0131\" }\n },\n {\n \"@type\": \"FAQPage\",\n \"mainEntity\": [\n {\"@type\": \"Question\", \"name\": \"Anti-HBs nedir?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Anti-HBs, hepatit B vir\u00fcs\u00fcn\u00fcn y\u00fczey antijenine (HBsAg) kar\u015f\u0131 olu\u015fan antikordur. Hepatit B a\u015f\u0131s\u0131ndan sonra ya da enfeksiyon iyile\u015ftikten sonra olu\u015fur ve ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n g\u00f6stergesi olarak kullan\u0131l\u0131r. Sonu\u00e7, HBsAg ve anti-HBc ile birlikte hekim taraf\u0131ndan yorumlan\u0131r.\"}},\n {\"@type\": \"Question\", \"name\": \"Anti-HBs pozitif ne demek?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Anti-HBs pozitifli\u011fi genel olarak hepatit B'ye kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k geli\u015fti\u011fini g\u00f6sterir. Bu ba\u011f\u0131\u015f\u0131kl\u0131k a\u015f\u0131dan ya da ge\u00e7irilmi\u015f enfeksiyondan gelebilir; ayr\u0131m i\u00e7in anti-HBc sonucuna bak\u0131l\u0131r. Yorum hekime aittir.\"}},\n {\"@type\": \"Question\", \"name\": \"Anti-HBs negatif ne demek?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Anti-HBs'nin negatif ya da referans de\u011ferin alt\u0131nda olmas\u0131, o anda koruyucu d\u00fczeyde antikor saptanmad\u0131\u011f\u0131 anlam\u0131na gelir. Bunun nedeni hi\u00e7 a\u015f\u0131lanmamak ya da kar\u015f\u0131la\u015f\u0131lmamak, a\u015f\u0131ya yeterli yan\u0131t olu\u015fmamas\u0131 veya antikorun zamanla azalmas\u0131 olabilir. Nedenin belirlenmesi HBsAg ve anti-HBc ile birlikte hekim taraf\u0131ndan yap\u0131l\u0131r.\"}},\n {\"@type\": \"Question\", \"name\": \"Anti-HBs ka\u00e7 olmal\u0131?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"A\u015f\u0131 serisini tamamlayan ki\u015filerde ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6stergesi olarak kullan\u0131lan genel k\u0131lavuz de\u011feri 10 mIU\/mL ve \u00fczeridir (CDC). Birim, y\u00f6ntem ve e\u015fik laboratuvara g\u00f6re de\u011fi\u015febilir; laboratuvar raporundaki aral\u0131k esast\u0131r.\"}},\n {\"@type\": \"Question\", \"name\": \"Anti-HBs y\u00fcksek \u00e7\u0131karsa ne demek?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Y\u00fcksek anti-HBs tek ba\u015f\u0131na bir hastal\u0131k belirtisi de\u011fildir; a\u015f\u0131ya ya da ge\u00e7irilmi\u015f enfeksiyona verilen g\u00fc\u00e7l\u00fc bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131 yans\u0131t\u0131r. Rapordaki say\u0131sal de\u011ferin b\u00fcy\u00fckl\u00fc\u011f\u00fc y\u00f6ntemle de ili\u015fkilidir. Sonu\u00e7 di\u011fer hepatit B testleriyle birlikte hekim taraf\u0131ndan yorumlan\u0131r.\"}},\n {\"@type\": \"Question\", \"name\": \"Anti-HBs zamanla d\u00fc\u015fer mi?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Evet, anti-HBs d\u00fczeyi zaman i\u00e7inde azalabilir. CDC'nin ACIP raporuna g\u00f6re a\u015f\u0131ya yan\u0131t vermi\u015f ve ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 normal ki\u015filerde d\u00fczey sonradan 10 mIU\/mL'nin alt\u0131na inse bile koruma s\u00fcrer. Bu de\u011ferlendirme hekime aittir.\"}},\n {\"@type\": \"Question\", \"name\": \"Hepatit B a\u015f\u0131s\u0131ndan sonra anti-HBs ne zaman bak\u0131l\u0131r?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"CDC'nin ACIP raporuna g\u00f6re, a\u015f\u0131 sonras\u0131 test gerekti\u011finde serinin son dozundan 1\u20132 ay sonra yap\u0131l\u0131r; rutin a\u015f\u0131lamada herkes i\u00e7in test \u00f6nerilmez. Hangi ki\u015filerde ve ne zaman bak\u0131laca\u011f\u0131na hekim karar verir.\"}}\n ]\n },\n {\n \"@type\": \"BreadcrumbList\",\n \"itemListElement\": [\n {\"@type\": \"ListItem\", \"position\": 1, \"name\": \"Ana Sayfa\", \"item\": \"https:\/\/merkezlaboratuvari.com\/\"},\n {\"@type\": \"ListItem\", \"position\": 2, \"name\": \"Anti-HBs Nedir?\", \"item\": \"https:\/\/merkezlaboratuvari.com\/anti-hbs-nedir\/\"}\n ]\n }\n ]\n}\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>Anti-HBs nedir sorusunun k\u0131sa yan\u0131t\u0131: anti-HBs, hepatit B vir\u00fcs\u00fcn\u00fcn y\u00fczey antijenine (HBsAg) kar\u015f\u0131 v\u00fccudun \u00fcretti\u011fi antikordur ve hepatit B&#8217;ye kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n g\u00f6stergesi olarak kullan\u0131l\u0131r. Pozitif sonu\u00e7 genellikle hepatit B a\u015f\u0131s\u0131na ya da iyile\u015fmi\u015f bir enfeksiyona ba\u011fl\u0131 ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131, negatif sonu\u00e7 ise o anda koruyucu d\u00fczeyde antikor saptanmad\u0131\u011f\u0131n\u0131 g\u00f6sterir. Bu sayfada anti-HBs&#8217;nin nas\u0131l olu\u015ftu\u011fu, pozitif, negatif ve [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-9373","post","type-post","status-publish","format-standard","hentry","category-saglik"],"_links":{"self":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/posts\/9373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/comments?post=9373"}],"version-history":[{"count":5,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/posts\/9373\/revisions"}],"predecessor-version":[{"id":9464,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/posts\/9373\/revisions\/9464"}],"wp:attachment":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/media?parent=9373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/categories?post=9373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/tags?post=9373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}